Differential time course of action of 5-HT 3 and NK 1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Supportive Care in Cancer

Volumn 19, Issue 9, 2011, Pages 1297-1302

  Hesketh, Paul J ^a   Warr, David G ^b   Street, James C ^c   Carides, Alexandra D ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Reagent   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 HT 3 receptor antagonist; Aprepitant; Chemotherapy induced nausea and vomiting; NK 1 receptor antagonist

Indexed keywords

ANTHRACYCLINE; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MORPHOLINES; MULTIVARIATE ANALYSIS; NAUSEA; NEOPLASMS; ONDANSETRON; RECEPTORS, NEUROKININ-1; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 80051582732     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0944-4     Document Type: Article

References (18)

1. CC Sun DC Bodurka CB Weaver R Rasu JK Wolf MW Bevers JA Smith JT Wharton EB Rubenstein 2005 Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer Support Care Cancer 13 219 227 15538640 10.1007/s00520-004-0710-6 (Pubitemid 40576508)
2. PJ Hesketh 2008 Chemotherapy-induced nausea and vomiting N Engl J Med 358 2482 2494 18525044 10.1056/NEJMra0706547 1:CAS:528:DC%2BD1cXmvFKltL0%3D (Pubitemid 351793021)
3. F Roila M Tonato F Cognetti E Cortesi G Favalli M Marangolo D Amadori MA Bella V Gramazio D Donati, et al. 1991 Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone J Clin Oncol 9 675 678 1829757 1:STN:280:DyaK3M3psVygug%3D%3D
4. DB Smith ES Newlands GJ Rustin RH Begent N Howells B McQuade KD Bagshawe 1991 Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy Lancet 338 487 490 1714532 10.1016/0140-6736(91)90555-4 1:STN:280:DyaK3Mzjtlamsg%3D%3D
5. PJ Hesketh WH Harvey WG Harker TM Beck T Ryan LJ Bricker JA Kish WK Murphy JD Hainsworth B Haley 1994 A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis J Clin Oncol 12 596 600 8120559 1:STN:280:DyaK2c7msFKqtA%3D%3D (Pubitemid 24079904)
6. R Tavorath PJ Hesketh 1996 Drug treatment of chemotherapy-induced delayed emesis Drugs 52 639 648 9118814 10.2165/00003495-199652050-00002 1:CAS:528:DyaK28XntF2qurg%3D (Pubitemid 26382184)
7. FD Tattersall W Rycroft M Cumberbatch G Mason S Tye DJ Williamson JJ Hale SG Mills PE Finke M MacCoss S Sadowski E Ber M Cascieri RG Hill DE MacIntyre RJ Hargreaves 2000 The novel nk1 receptor antagonist mk-0869 (l-754, 030) and its water soluble phosphoryl prodrug, l-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets Neuropharmacology 39 652 663 10728886 10.1016/S0028-3908(99)00172-0 1:CAS:528:DC%2BD3cXhtFWqs7w%3D (Pubitemid 30089315)
8. S Poli-Bigelli J Rodrigues-Pereira AD Carides G Julie Ma K Eldridge A Hipple JK Evans KJ Horgan F Lawson 2003 Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in latin america Cancer 97 3090 3098 12784346 10.1002/cncr.11433 1:CAS:528:DC%2BD3sXlt1Shu7k%3D (Pubitemid 36676265)
9. PJ Hesketh SM Grunberg RJ Gralla DG Warr F Roila R de Wit SP Chawla AD Carides J Ianus ME Elmer JK Evans K Beck S Reines KJ Horgan 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112 4119 14559886 10.1200/JCO.2003.01.095 1:CAS:528:DC%2BD2cXpsVajtr0%3D (Pubitemid 46606178)
10. HJ Schmoll MS Aapro S Poli-Bigelli HK Kim K Park K Jordan J von Pawel H Giezek T Ahmed CY Chan 2006 Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Ann Oncol 17 1000 1006 16524979 10.1093/annonc/mdl019 1:STN:280:DC%2BD283nsleguw%3D%3D (Pubitemid 43778994)
11. PJ Hesketh S Van Belle M Aapro FD Tattersall RJ Naylor R Hargreaves AD Carides JK Evans KJ Horgan 2003 Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur J Cancer 39 1074 1080 12736106 10.1016/S0959-8049(02)00674-3 1:CAS:528:DC%2BD3sXjsVarurk%3D (Pubitemid 36555864)
12. DG Warr PJ Hesketh RJ Gralla HB Muss J Herrstedt PD Eisenberg H Raftopoulos SM Grunberg M Gabriel A Rodgers N Bohidar G Klinger CM Hustad KJ Horgan F Skobieranda 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830 15837996 10.1200/JCO.2005.09.050 1:CAS:528:DC%2BD2MXktleqt74%3D (Pubitemid 46179473)
13. M Martin 1996 The severity and pattern of emesis following different cytotoxic agents Oncology 53 Suppl 1 26 31 8692547 10.1159/000227637 (Pubitemid 26335146)
14. F Roila D Donati S Tamberi G Margutti 2002 Delayed emesis: incidence, pattern, prognostic factors and optimal treatment Support Care Cancer 10 88 95 11862498 10.1007/s005200100295 (Pubitemid 36056305)
15. V Cocquyt S Van Belle R Reinhardt, et al. 2001 L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, compared to ondansetron for the prevention of cisplatin-induced emesis Eur J Cancer 37 835 842 11313170 10.1016/S0959-8049(00)00416-0 1:CAS:528:DC%2BD3MXislGhtLc%3D (Pubitemid 32323960)
16. D Campos JR Pereira R Reinhardt, et al. 2001 Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, aprepitant, in combination with granisetron and dexamethasone or with dexamethasone alone J Clin Oncol 19 1759 1767 11251007 1:CAS:528:DC%2BD3MXisFygs7Y%3D (Pubitemid 32230878)
17. PJ Hesketh 1999 Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice Oncologist 4 191 196 10394587 1:STN:280:DyaK1Mzit1yqsw%3D%3D (Pubitemid 29297482)
18. SM Grunberg M Dugan H Muss M Wood S Burdette-Radoux T Weisberg M Siebel 2009 Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy Support Care Cancer 17 589 594 19037667 10.1007/s00520-008-0535-9